However, the elevation of CXCL9 in patients with MASLD might also point to this chemokine as the initial activator of many pathways that ultimately lead to fibrosis and culminate in the development and progression of MASLD. The gene discussed is CXCL9; the disease is metabolic dysfunction-associated steatotic liver disease.